Figure 2

(A) Event-free survival analysis in the 36 patients with p53 overexpressing tumours and the 43 patients with p53 negative tumours. (B) Event-free survival analysis in the 38 patients with VEGF positive tumours and the 41 patients with VEGF negative tumours.